Literature DB >> 31314075

Adherence to Antiretroviral Therapy and Pre-exposure Prophylaxis: TARGETing the Ideal Measure.

Jose R Castillo-Mancilla1.   

Abstract

Keywords:  adherence; antiretroviral therapy; pre-exposure prophylaxis; tenofovir; urine

Year:  2020        PMID： 31314075      PMCID： PMC7201412          DOI： 10.1093/cid/ciz651

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  19 in total

1.  Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.

Authors:  Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden
Journal:  Lancet Infect Dis       Date:  2014-07-22       Impact factor: 25.071

Review 2.  Technological methods to measure adherence to antiretroviral therapy and preexposure prophylaxis.

Authors:  Lindsey E Garrison; Jessica E Haberer
Journal:  Curr Opin HIV AIDS       Date:  2017-09       Impact factor: 4.283

3.  A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure.

Authors:  A Gonzalez-Serna; L C Swenson; B Watson; W Zhang; A Nohpal; K Auyeung; J S Montaner; P R Harrigan
Journal:  Clin Microbiol Infect       Date:  2016-08-30       Impact factor: 8.067

4.  Pharmacologic-Based Methods of Adherence Assessment in HIV Prevention.

Authors:  Kristina M Brooks; Peter L Anderson
Journal:  Clin Pharmacol Ther       Date:  2018-09-04       Impact factor: 6.875

5.  Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda.

Authors:  Jessica E Haberer; Nicholas Musinguzi; Yap Boum; Mark J Siedner; A Rain Mocello; Peter W Hunt; Jeffrey N Martin; David R Bangsberg
Journal:  J Acquir Immune Defic Syndr       Date:  2015-12-01       Impact factor: 3.731

6.  A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.

Authors:  J L O'Connor; E M Gardner; S Esser; S B Mannheimer; A R Lifson; E E Telzak; A N Phillips
Journal:  HIV Med       Date:  2015-07-17       Impact factor: 3.180

7.  Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy.

Authors:  Monica Gandhi; Niloufar Ameli; Peter Bacchetti; Kathryn Anastos; Stephen J Gange; Howard Minkoff; Mary Young; Joel Milam; Mardge H Cohen; Gerald B Sharp; Yong Huang; Ruth M Greenblatt
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

8.  "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients.

Authors:  Thomas J Podsadecki; Bernard C Vrijens; Eric P Tousset; Richard A Rode; George J Hanna
Journal:  HIV Clin Trials       Date:  2008 Jul-Aug

9.  Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test.

Authors:  Monica Gandhi; Peter Bacchetti; Matthew A Spinelli; Hideaki Okochi; Jared M Baeten; Oraphan Siriprakaisil; Virat Klinbuayaem; Warren C Rodrigues; Guohong Wang; Michael Vincent; Tim R Cressey; Paul K Drain
Journal:  J Acquir Immune Defic Syndr       Date:  2019-05-01       Impact factor: 3.731

10.  A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.

Authors:  Tim R Cressey; Oraphan Siriprakaisil; Virat Klinbuayaem; Justice Quame-Amaglo; Rachel W Kubiak; Pra-Ornsuda Sukrakanchana; Kanchana Than-In-At; Jared Baeten; Wasna Sirirungsi; Ratchada Cressey; Paul K Drain
Journal:  BMC Infect Dis       Date:  2017-07-14       Impact factor: 3.090
View more
  1 in total

Review 1.  Tenofovir alafenamide use in pregnant and lactating women living with HIV.

Authors:  Ahizechukwu C Eke; Kristina M Brooks; Rahel D Gebreyohannes; Jeanne S Sheffield; Kelly E Dooley; Mark Mirochnick
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-03-17       Impact factor: 4.936
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.